Slides with transcript embedded Download (PDF)
Audio download of live meeting
||Gaylord National Resort and Convention Center
||Thursday, Mar 7, 2013 6:30 AM
||To register scroll down.
With the recent approval of many novel agents there have been significant changes in the treatment landscape for melanoma. Surgical oncologists, plastic surgeons, and ENT and general surgeons play a crucial role in the diagnosis, staging, and management of melanoma. Therefore, there is a growing need for educational activities targeting these surgical specialists and providing guidance on the mechanisms of action and safety and efficacy profiles of emerging agents for the care of patients with advanced melanoma in the community setting. This program is designed to fill that need, and will update surgical specialists on advances in the management of melanoma.
This presentation was selected by the Society of Surgical Oncology as an independent educational activity held at the site of the 2013 Annual Cancer Symposium. This presentation is not sponsored or endorsed by the Society of Surgical Oncology.
Charles M. Balch, MD, FACS (Moderator)
Editor-in-Chief, Annals of Surgical Oncology
Professor of Surgery
Division of Surgical Oncology
University of Texas Southwestern Medical Center
Paul B. Chapman, MD
Attending Physician, Melanoma/Sarcoma Service
Department of Medicine, Memorial Sloan-Kettering Cancer Center
Professor of Medicine, Weill-Cornell Medical School
New York, NY
Jeffrey E. Gershenwald, M.D.
Professor, Department of Surgical Oncology
Professor, Department of Cancer Biology
Medical Director, Melanoma and Skin Center
The University of Texas MD Anderson Cancer Center
Vernon K. Sondak, MD
Division Chief, Cutaneous Oncology
Director of Surgical Education
H. Lee Moffitt Cancer Center and Research Institute
This activity is intended for surgical oncologists, plastic surgeons, and ENT and general surgeons who are involved in the treatment of patients with melanoma.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Assess emerging efficacy and safety data from recently approved novel agents for the treatment of melanoma
- Identify key investigational agents from currently ongoing clinical trials in melanoma and counsel patients accordingly
- Understand the role of biomarkers in personalizing therapy for metastatic melanoma
- Develop a multidisciplinary treatment approach for the management of melanoma
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Requirements to Earn CME/MOC Credit
To receive continuing medical education (CME) and MOC Part II certification credit, participants must view the content, successfully complete the self-assessment exam and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the corresponding rationale. Learners will be able to review the content and repeat the self-assessment exam as many times needed. Upon achieving a score of 75% or higher on all of the modules, learners will be asked to complete a post-activity evaluation. A CME/MOC certificate will be available to print upon successful submission of the post-activity evaluation.
Estimated Time to Complete Activity
The estimated time to complete this entire activity is 1 hour.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Maintenance of Certification (MOC) Credit is only for surgeons who are involved in the treatment of patients with cancer. The Potomac Center for Medical Education under the American Board of Surgery MOC Criteria has approved this activity for up to 1 MOC Part II certification points.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Paul B. Chapman, MD – Consulting fee: GlaxoSmithKline, Roche/Genentech
Jeffrey E. Gershenwald, MD – Advisory Board: GlaxoSmithKline, Navidea
Charles M. Balch, MD FACS – Speaker: Merck; Consulting: Amgen
Vernon K. Sondak, MD – Consultant/Advisory Board: Bristol-Myers Squibb, GlaxoSmithKline, Merck, Navidea, Provectus; Speakers Bureau: Merck
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Latha Shivakumar, PhD, CCMEP; Bradley Pine; Blair St. Amand; Jay Katz, CCMEP; CME Peer Review: Nothing to Disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
There is no fee for this program.
Jointly Sponsored By
This continuing educational activity is supported by an independent educational grant from Merck.
By clicking the Registration Button below you are agreeing that you have read and understood the CE Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.